The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: A study of health-related quality of life

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 3, 2015, Pages 286-295

  Younossi, Z M ^a,b   Stepanova, M ^a,b   Nader, F ^a,b   Lam, B ^a,b   Hunt, S ^a,b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; ARTICLE; CHRONIC HEPATITIS C; FEMALE; HEALTH STATUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; COMPARATIVE STUDY; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; QUESTIONNAIRE; TREATMENT WITHDRAWAL;

ADULT; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MENTAL HEALTH; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RIBAVIRIN; SOFOSBUVIR; SURVEYS AND QUESTIONNAIRES; WITHHOLDING TREATMENT;

EID: 84936846849     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13269     Document Type: Article

References (21)

1. Willke RJ, Burke LB, Erickson P,. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004; 25: 535-52.
2. Younossi Z, Henry L,. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014; 46S5: S186-96. doi: 10.1016/j.dld.2014.09.025
3. Hays RD, Morales LS,. The RAND-36 measure of health-related quality of life. Ann Med 2001; 33: 350-7.
4. Brazier J, Roberts J, Deverill M,. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271-92.
5. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
6. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
7. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
8. Afdhal N, Reddy KR, Nelson DR, et al,. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
9. Kowdley KV, Gordon SC, Reddy KR, et al,. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
10. Sulkowski MS, Naggie S, Lalezari J, et al,. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014; 312: 353.
11. Younossi ZM, Stepanova M, Zeuzem S, et al,. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol 2014; 61: 228-34.
12. Younossi ZM, Stepanova M, Nader F, et al,. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014; 59: 2161-9.
13. Younossi ZM, Stepanova M, Henry L, et al,. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014; 12: 1349-59. e13.
14. Stepanova M, Nader F, Cure S, Bourhis F, Hunt S, Younossi ZM,. Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther 2014; 40: 676-85.
15. Younossi ZM, Stepanova M, Henry L, et al,. Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C. J Hepatol 2014; 60: 741-7.
16. Younossi ZM, Stepanova M, Sulkowski M, et al,. Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: the Impact on Patient-Reported Outcomes. J Infect Dis 2015; doi: 10.1093/infdis/jiv005 [Epub ahead of print]
17. Younossi ZM, Stepanova M, Marcellin P, et al,. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, 2 and 3 clinical trials. Hepatology 2015; doi: 10.1002/hep.27724 [Epub ahead of print]
18. Younossi ZM, Stepanova M, Afdhal N, et al,. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015; doi: 10.1016/j.jhep.2015.03.014 [Epub ahead of print]
19. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F,. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.
20. Dan AA, Kallman JB, Srivastava R, Younoszai Z, Kim A, Younossi ZM,. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl 2008; 14: 321-6.
21. Bonkovsky HL, Snow KK, Malet PF, et al,. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 2007; 46: 420-31.